Clinical trial NCT01520103: Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
Official title: Randomized Phase II Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Her2-negative Metastatic Breast Cancer
Her2-negative Locally Advanced Breast Cancer
Keywords: Metastatic breast cancer
locally advanced breast cancer
Her2/new negative
HER2 negative
Lead sponsor: AIO-Studien-gGmbH
Sponsor class: OTHER
Collaborators: name: iOMEDICO AG
name: Novartis Pharmaceuticals
First posted: 2012-01-27
Enrollment: 139
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is Examination of the superiority of a combination of vinorelbine with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in advanced breast cancer.


Eligibility criteria: Inclusion Criteria:

1 .Dated and signed patient informed consent before start of any in the protocol specified procedures 2. Histologically or cytologically confirmed Her2/neu negative, metastatic or locally advanced breast cancer, including inoperable local relapse, with measurable or non-measurable lesions for which

* a palliative second line chemotherapy is indicated. Antihormone palliative pretreatments do not count as separate treatment lines
* treatment with anthracycline and/or taxanes has failed or is not suitable
* which cannot be adequately treated by operation or radiotherapy on its own 3. An exclusive anti-hormone therapy is not indicated for the patient 4. ECOG Performance Status of 0-2 5. Women \>= 18 years of age 6. Life expectancy of at least 12 weeks 7. Adequate bone marrow, liver and renal function (according to SmPC of Vinorelbine, Afinitor®) based on laboratory assessments raised within 7 days prior to start of study treatment:
* Haemoglobin \>= 9.0 g/dl
* Absolute neutrophil count (ANC) \>= 2/mm³
* Thrombocytes \>= 100/µl
* INR \>= 2
* Serum bilirubin =\< 1.5x upper limit of normal ( in patients with known Gilbert syndrome, total bilirubin =\< 3x upper limit of normal, with direct bilirubin =\< 1.5x upper limit of normal
* ALT and AST =\< 2.5x upper limit of normal (=\< 5x upper limit of normal in subjects with liver metastases)
* Serum cholesterol =\< 300 mg/dl or 7.75 mmol/l and triglycerides =\< 2.5x upper limit of normal (with lipid lowering drugs permitted)
* Serum creatinin =\< 2x upper limit of normal 8. Documentation of a negative pregnancy test in women of childbearing potential within 7 days prior to start of study. Sexual active pre-menopausal women are required to use adequate contraception throughout the duration of the study, except for oestrogen containing contraceptives

Exclusion Criteria:

1. Previous treatment with Vinorelbine or an inhibitor of mTOR
2. Treatment with other study medication within 28 days before start of treatment
3. Patients who have received prior radiotherapy to ≥ 25% of the bone marrow
4. Other tumours in the previous 5 years with exception of an adequately treated basal cell carcinoma of the skin or a preinvasive cervix carcinoma
5. Simultaneous use of known CYP3A4 inducers (e.g. Phenytoin, Rifampicin) or inhibitors of this enzyme (e.g. Itraconazole, Ketoconazole), therefore also use of mistletoe, St John's wort or grapefruit juice
6. Patients to whom at least one of the conditions applies:

   * Substance abuse
   * medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results as judged by the investigator
   * Legal incapacity or limited legal capacity
   * Subjects who are unable to take oral medication
   * Any condition that could jeopardise the safety of the patient and their compliance in the study as judged by the investigator
7. History of cardiac dysfunction including one of the following:

   * Myocardial infarction by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function
   * History of documented congestive heart failure (NYHA ≥ 3)
   * Documented cardiomyopathy
8. Known HIV infection or chronic hepatitis B or C or history of hepatitis B / C
9. Active clinically relevant infection (\> grade 2 NCI-CTC Version 4.03)
10. Clinical or radiological detection of CNS metastases
11. Patients receiving concomitant immunosuppressive agents or chronic use of corticosteroids at the time of study entry except in cases outlined below:

    * topical applications (e.g. rash,) inhaled sprays, (e.g. obstructive airway diseases) eye drops or local injections (e.g. intraarticular) are allowed
12. Active bleeding diathesis or an oral anti-vitamin K medication (except low-dose warfarin and aspirin or equivalent, as long as the INR ≤ 2)
13. Kidney function disorder requiring dialysis
14. Seriously impaired liver function (Child-Pugh, class C)
15. Known hypersensitivity reaction to Vinorelbine or Everolimus
16. Pregnant or breast-feeding subjects

Primary outcomes:
measure: Progression-free survival (PFS)
timeFrame: Assessment over 36 months, minimum 12 month
Secondary outcomes:
measure: Safety and tolerability
timeFrame: Assessment over 36 months
measure: Rate of Progression Free Survival after 6 months (6 months PFSR)
timeFrame: Assessment over 36 months
measure: Overall survival (OS)
timeFrame: 36 months
measure: Response rate (CR, PR)
timeFrame: 36 months
Other outcomes:
Locations:
city: Münster
country: Germany
facility: Hämatologisch-onkologische Gemeinschaftspraxis, Münster
Study officials:
affiliation: Hämatologisch-onkologische Gemeinschaftspraxis, Münster
name: Christian Lerchenmüller, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, Schroder H, Jaehnig P, Potthoff K, Lerchenmuller C. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer. Breast Cancer Res Treat. 2019 Aug;176(3):637-647. doi: 10.1007/s10549-019-05280-2. Epub 2019 May 21.